



## BRINGING A BREATH OF FRESH AIR TO RESPIRATORY DISEASE PATIENTS

Aiming to transform lives by treating diseases caused by epithelial dysfunction

### The Company

- EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company with a unique approach to developing drugs for chronic inflammatory diseases, focusing on enhancing epithelial integrity.
- Our novel approach targets enhancement of epithelial integrity of the airway as a causal pathway of inflammation and disease.
- Epithelial cells are a key part of the barrier that makes up lung tissue and other organs. A breakdown of this barrier is implicated in several chronic inflammatory diseases.
- EpiEndo's new class of orally available, macrolide with limited antibiotic effect or 'Barriolide™', shows promise as an effective option for chronic respiratory diseases as well as other inflammatory indications.
- Initial focus in on Chronic Obstructive Pulmonary Disease (COPD)
- Using macrolides with reduced antibiotic effect in inflammatory disorders helps resolve the issue of Anti-Microbial Resistance (AMR) development during long-term use.

### The Market

- COPD is one of the leading causes of death globally, causing progressive airflow obstruction. There is currently no cure for the disease.
- Current COPD therapies are predominantly inhaled and mainly offer symptomatic relief, but do not alter the progression of the disease.
- Significant unmet medical need for effective therapies in COPD
- Global COPD therapeutic market is projected to reach US\$20 billion by 2020

### Pipeline

- Lead asset, EP395 is an oral, barrier-enhancing, pro-epithelial drug which reduces inflammation, designed to address chronic airway diseases.
- It is currently in the clinic in a Phase 2a study in COPD patients.
- As an oral, barrier-enhancing, pro-epithelial drug which reduces inflammation, EP395 has broad expansion potential for other airway diseases and inflammatory indications.
- EpiEndo is expanding its pipeline to include additional indication areas, including the skin and gut.
- It aims to be the first oral, barrier strengthening and anti-inflammatory macrolide on the market for the treatment of COPD.

### Fast Facts

#### Established:

2014

#### Headquarters:

Reykjavik, Iceland

#### Therapeutic Area:

Chronic inflammatory and respiratory disease

#### Technology:

Developing a new class of non-antibiotic macrolides, "Barriolides™", focused on strengthening the integrity of the lung epithelium, to slow respiratory disease progression by reducing inflammation

#### Advantages:

- Oral treatment
- Broad market potential
- No major side effects expected
- More sustainable than current treatments

#### Development Stage:

- Clinical-stage biopharmaceutical company
- EP395 currently in Phase 2a studies in COPD patients

#### Funds Raised:

€31.7 million raised so far in Seed and Series A funding from private and institutional investors

#### Intellectual property:

Strong IP position, with patents protecting pipeline of therapeutic assets

#### Executive Leadership:

Maria Bech, MSc – CEO

Stefán Pétursson, MBA – CFO

Fridrik Gardarsson, MD – Chief Innovation Officer

Finnur Einarsson – COO

Jennifer Krickler, PhD – Director of Preclinical Research

Ginny Norris, PhD – CMO and Head of Development

[www.epiendocom](http://www.epiendocom)

Updated: June 2023